BEUDAMED
    FDA Adverse Event Injury Summary report: N

    DENTAL-AMALGAM

    MDR report key: 14548346 · Received May 27, 2022

    Report

    Report Number
    MW5109994
    Event Type
    Injury
    Date Received
    May 27, 2022
    Report Date
    May 25, 2022
    Manufacturer
    UNK
    Product Code
    OIV
    Adverse Event
    Yes
    Product Problem
    Yes
    Report Source
    Voluntary report
    Reporter Location
    IL, US
    Reporter Occupation
    PATIENT
    Health Professional
    *

    Narratives

    Description of Event or Problem · 0

    I WAS DIAGNOSED WITH MULTIPLE SCLEROSIS AND LATER BELIEVED TO BELIEVE IT BECAUSE MY DENTAL AMALGAM MERCURY FILLINGS AS MY IDENTICAL TWIN DID NOT HAVE THESE FILLINGS. THIS BELIEF WAS LATER CONFIRMED BY THE POSITION STATEMENT SENT OUT BY THE FDA ON SEPT, 24, 2020. IT STATED THAT CAUTION SHOULD BE TAKEN IN HIGH-RISK INDIVIDUALS (GENETICALLY - PREDISPOSED). THIS GIVES MORE VALIDITY BETWEEN THE CONNECTION BETWEEN THESE MERCURY FILLINGS AND MY MS. MY TWIN SHOULD NOT GET THESE FILLINGS AS IT CAN UNMASK HIS LATENT MS. FDA SAFETY REPORT ID # (B)(4).

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    2197526 DENTAL-AMALGAM DENTAL-AMALGAM OIV UNK

    Patients

    Seq Age Sex Outcome Treatment
    1 34 YR Male Hospitalization| O TECHFIDERA - STOPPED AFTER < 1 YEAR OF USE| THE MERCURY REMOVAL PROCESS INVOLVES THE FOLLOWING: ALPHA LIPOIC ACID [TIMED RELEASE], A POWERFUL CHELATOR/ANTI-OXIDANT CAPABLE OF CROSSING THE BLOOD-BRAIN BARRIER AND BINDING TO MERCURY, COQ 10, VITAMINS A, B, C, D, AND E, MSM,SELENIUM, MAGNESIUM, LITHIUM, BORON, MILK THISTLE, TURMERIC, AND ZINC